Listen Up

Monday, November 18, 2024

A.I. Chatbots Defeated Doctors at Diagnosing Illness


A small study found ChatGPT outdid human physicians when assessing medical case histories, even when those doctors were using a chatbot.

Gina Kolata

By Gina Kolata

Nov. 17, 2024

Dr. Adam Rodman, an expert in internal medicine at Beth Israel Deaconess Medical Center in Boston, confidently expected that chatbots built to use artificial intelligence would help doctors diagnose illnesses.


He was wrong.

Instead, in a study Dr. Rodman helped design, doctors who were given ChatGPT-4 along with conventional resources did only slightly better than doctors who did not have access to the bot. And, to the researchers’ surprise, ChatGPT alone outperformed the doctors.

“I was shocked,” Dr. Rodman said.

The chatbot, from the company OpenAI, scored an average of 90 percent when diagnosing a medical condition from a case report and explaining its reasoning. Doctors randomly assigned to use the chatbot got an average score of 76 percent. Those randomly assigned not to use it had an average score of 74 percent.

The study showed more than just the chatbot’s superior performance.

It unveiled doctors’ sometimes unwavering belief in a diagnosis they made, even when a chatbot potentially suggests a better one.

The study illustrated that while doctors are being exposed to the tools of artificial intelligence for their work, few know how to exploit the abilities of chatbots. As a result, they failed to take advantage of A.I. systems’ ability to solve complex diagnostic problems and offer explanations for their diagnoses.

A.I. systems should be “doctor extenders,” Dr. Rodman said, offering valuable second opinions on diagnoses.

But it looks as if there is a way to go before that potential is realized.

Case History, Case Future

The experiment involved 50 doctors, a mix of residents and attending physicians recruited through a few large American hospital systems, and was published last month in the journal JAMA Network Open.

The test subjects were given six case histories and were graded on their ability to suggest diagnoses and explain why they favored or ruled them out. Their grades also included getting the final diagnosis right.


The graders were medical experts who saw only the participants’ answers, without knowing whether they were from a doctor with ChatGPT, a doctor without it, or from ChatGPT by itself.

The case histories used in the study were based on real patients and are part of a set of 105 cases that have been used by researchers since the 1990s. The cases intentionally have never been published so that medical students and others could be tested on them without any foreknowledge. That also meant that ChatGPT could not have been trained on them.


But, to illustrate what the study involved, the investigators published one of the six cases the doctors were tested on, along with answers to the test questions on that case from a doctor who scored high and from one whose score was low.

That test case involved a 76-year-old patient with severe pain in his low back, buttocks and calves when he walked. The pain started a few days after he had been treated with balloon angioplasty to widen a coronary artery. He had been treated with the blood thinner heparin for 48 hours after the procedure.

The man complained that he felt feverish and tired. His cardiologist had done lab studies that indicated a new onset of anemia and a buildup of nitrogen and other kidney waste products in his blood. The man had had bypass surgery for heart disease a decade earlier.

The case vignette continued to include details of the man’s physical exam and then provided his lab test results.

The correct diagnosis was cholesterol embolism — a condition in which shards of cholesterol break off from plaque in arteries and block blood vessels.

Participants were asked for three possible diagnoses, with supporting evidence for each. They also were asked to provide, for each possible diagnosis, findings that do not support it or that were expected but not present.

The participants also were asked to provide a final diagnosis. Then they were to name up to three additional steps they would take in their diagnostic process.

Like the diagnosis for the published case, the diagnoses for the other five cases in the study were not easy to figure out. But neither were they so rare as to be almost unheard-of. Yet the doctors on average did worse than the chatbot.

What, the researchers asked, was going on?

The answer seems to hinge on questions of how doctors settle on a diagnosis, and how they use a tool like artificial intelligence.

The Physician in the Machine

How, then, do doctors diagnose patients?

The problem, said Dr. Andrew Lea, a historian of medicine at Brigham and Women’s Hospital who was not involved with the study, is that “we really don’t know how doctors think.”

In describing how they came up with a diagnosis, doctors would say, “intuition,” or, “based on my experience,” Dr. Lea said.

That sort of vagueness has challenged researchers for decades as they tried to make computer programs that can think like a doctor.

The quest began almost 70 years ago.

“Ever since there were computers, there were people trying to use them to make diagnoses,” Dr. Lea said.

One of the most ambitious attempts began in the 1970s at the University of Pittsburgh. Computer scientists there recruited Dr. Jack Myers, chairman of the medical school’s department of internal medicine who was known as a master diagnostician. He had a photographic memory and spent 20 hours a week in the medical library, trying to learn everything that was known in medicine.

Dr. Myers was given medical details of cases and explained his reasoning as he pondered diagnoses. Computer scientists converted his logic chains into code. The resulting program, called INTERNIST-1, included over 500 diseases and about 3,500 symptoms of disease.

To test it, researchers gave it cases from the New England Journal of Medicine. “The computer did really well,” Dr. Rodman said. Its performance “was probably better than a human could do,” he added.

But INTERNIST-1 never took off. It was difficult to use, requiring more than an hour to give it the information needed to make a diagnosis. And, its creators noted, “the present form of the program is not sufficiently reliable for clinical applications.”

Research continued. By the mid-1990s there were about a half dozen computer programs that tried to make medical diagnoses. None came into widespread use.

“It’s not just that it has to be user-friendly, but doctors had to trust it,” Dr. Rodman said.

And with the uncertainty about how doctors think, experts began to ask whether they should care. How important is it to try to design computer programs to make diagnoses the same way humans do?

“There were arguments over how much a computer program should mimic human reasoning,” Dr. Lea said. “Why don’t we play to the strength of the computer?”

The computer may not be able to give a clear explanation of its decision pathway, but does that matter if it gets the diagnosis right?

The conversation changed with the advent of large language models like ChatGPT. They make no explicit attempt to replicate a doctor’s thinking; their diagnostic abilities come from their ability to predict language.

“The chat interface is the killer app,” said Dr. Jonathan H. Chen, a physician and computer scientist at Stanford who was an author of the new study.

“We can pop a whole case into the computer,” he said. “Before a couple of years ago, computers did not understand language.”

However many doctors may not be exploiting its potential.Operator Error

After his initial shock at the results of the new study, Dr. Rodman decided to probe a little deeper into the data and look at the actual logs of messages between the doctors and ChatGPT. The doctors must have seen the chatbot’s diagnoses and reasoning, so why didn’t those using the chatbot do better?

It turns out that the doctors often were not persuaded by the chatbot when it pointed out something that was at odds with their diagnoses. Instead, they tended to be wedded to their own idea of the correct diagnosis.

“They didn’t listen to A.I. when A.I. told them things they didn’t agree with,” Dr. Rodman said.

That makes sense, said Laura Zwaan, who studies clinical reasoning and diagnostic error at Erasmus Medical Center in Rotterdam and was not involved in the study.

“People generally are overconfident when they think they are right,” she said.

But there was another issue: Many of the doctors did not know how to use a chatbot to its fullest extent.

Dr. Chen said he noticed that when he peered into the doctors’ chat logs, “they were treating it like a search engine for directed questions: ‘Is cirrhosis a risk factor for cancer? What are possible diagnoses for eye pain?  “It was only a fraction of the doctors who realized they could literally copy-paste the entire case history into the chatbot and just ask it to give a comprehensive answer to the entire question,” Dr. Chen added.

“Only a fraction of doctors actually saw the surprisingly smart and comprehensive answers the chatbot was capable of producing.”


Wednesday, November 13, 2024

8 Top Pharma Trends In The Digital Health and AI Era - The Medical Futurist

One area of. AI adoption is in PHARMA. The reasons are simple



1. Large corporations have significant resources.
2. Intense competition.
3. Regulatory effects from CMS, and FDA

Amid the digital health era, the pharmaceutical industry has been experiencing a rapid evolution. Thanks to the new paradigms that novel healthcare delivery approaches and digital health technologies have brought about, pharma companies need to adopt new strategies and consider new investment opportunities to stay relevant in the ever-evolving healthcare landscape.

In this article, we cover 8 major trends for pharma companies to consider in the digital health era. We rank them based on their return on investment (ROI) and return on vision (ROV). The latter is particularly relevant in this era considering its rapid rate of evolution. 

To better appreciate the importance of ROV, we can consider the Apollo program. While it was focused on space exploration, the endeavour has resulted in a multitude of spin-off products across various fields. In the healthcare sector, those spin-offs range from medical imaging to innovations in dental care. 

As such, current investments can have wide-ranging applications in the future. From AI in drug development to digital therapeutics, a host of new technologies and trends hold promising ROI and ROV for pharma companies.

We share a collection of 8 major ones below, ordered from the most practical and promising to the least

The niche is rich in  applications

1. Artificial Intelligence for drug research and development

The process of drug research and development has traditionally been a time-consuming and labor-intensive one. This has involved considerable trial-and-error research before a drug can proceed to further developmental stages. This process can be made more time- and cost-efficient with the assistance of artificial intelligence (AI).

AI models, such as those developed by Benevolent AI, can analyze significant amounts of datasets from scientific literature, clinical records, and chemical databases in a more time-efficient manner than humans can. From this information, they can precisely identify targets and how potential drugs will interact with them.

Companies like Schrödinger and Google DeepMind have used AI for drug formulation. Their software predicts the behavior of drug candidates and assesses their safety and effectiveness.

2. New reimbursement models

Pharma companies can tap into the new healthcare experience that patients can have in the digital health era to offer more than just medication. By combining medication and technology packages, they can offer more enticing reimbursement models for both payers and providers.

There have been several examples of such innovative models in the past that combine pharmaceuticals with technology. GSK has worked with Propeller Health on smart inhalers. Partners Healthcare Center and Japanese drug maker Daichii-Sankyo teamed up to bring a connected wearable for patients with atrial fibrillation.

Digital tools have been shown to improve health outcomes while minimizing financial costs. With such offerings, pharma companies can make their products stand out while being beneficial for both patients and insurance providers.

3. Large language models for improved workflow and customer service

Large language models (LLMs) have been popularised by tools such as ChatGPT and Google Gemini. Beyond the hype, the technology is a practical trend in the pharma industry.  LLMs can boost a company’s efficiency by optimizing internal operations and customer service.

Roche’s internal LLM tool, Roche GPT, assists the pharma company’s team in optimizing repetitive tasks and sharing knowledge. The tool further supports their business by automating structured data extraction about therapies and patients from scientific articles and clinical test results. Pfizer has also deployed a similar tool to help with its marketing efforts.

LLMs could further be used to improve customer service. With an LLM-powered chatbot, patients can get answers to their queries such as medication side effects in their native language

4. Automation in the supply chain

The pharma industry’s supply chain stands to gain a lot by embracing automation in its midst. For example, by integrating AI, drug shortages can be averted. By analyzing data from various sources, AI software can forecast potential disruptions and suggest adequate measures to ensure a steady supply of essential medication.


Automation in the supply chain does not only involve AI software but robotics is also part of the picture. Denso Robotics’ robots are capable of automating tasks in the manufacturing process. Exoskeletons are another example of robotics assistance. While not fully automating tasks, they augment manual factory worker’s ability to carry heavy loads and work in uncomfortable positions. In the future, we can even expect automated drone deliveries to be carried out within manufacturing sites and beyond.

5. Digital therapeutics 

Using software as treatment might have sounded like a science fiction concept a decade or so ago, but this prospect is very real and promising with the advent of digital therapeutics (DTx). DTx can be described as evidence-based software applications designed to prevent, manage, or treat medical conditions.

The accessibility, privacy, and minimal side effects that DTx provides have enticed pharma companies to invest in this trend. Pfizer has teamed with Sidekick Health to launch a DTx solution for atopic dermatitis. Eli Lilly also partnered with Sidekick Health to develop apps to support breast cancer treatment. 

Other companies like RelieVRx or HelloBetter integrate cognitive behavioral therapy principles in their apps to ease chronic pain. We share more promising DTx examples in a dedicated article.

6. in silico clinical trials

in silico clinical trials promise to enable the conduction of experiments wholly via computer simulation, without the need for animal or human testing. By running drug trials on computer simulations of organs, this approach can be both time and cost-effective while circumventing the side effects on live participants. 


While this promise has yet to be fully realized, progress has been made towards it. The Wyss Institute has developed organs-on-a-chip to emulate the complex structures and functions of living human organs. Their technology has been leveraged by Emulate Inc. for efficient drug development. The mathematical model of human physiology created by HumMod has been used in several research projects. Further envisioning a future trending towards in silico trials, the Virtual Physiological Human Institute has been set up to encourage the effective adoption of in silico medical research.

For further reading please click on this link


8 Top Pharma Trends In The Digital Health and AI Era - The Medical Futurist

How will the Trump Administration Affect Medicine and Healthcare

The Trump administration's impact on medicine can be analyzed through several key areas:

Healthcare Policy**

Affordable Care Act (ACA)**: Efforts will be made to repeal and replace the ACA, which could have affected coverage for millions.

Medicare and Medicaid**: Proposals to reduce funding or change eligibility could impact access to healthcare for vulnerable populations.

FDA (Food and Drug Administration

President-elect Trump stated he will clean up the FDA, to eliminate waste and improve transparency as well as modernize drug and vaccine approvals. Robert F. Kennedy Jr has been mentioned as a possible candidate to head the FDA.

Drug Pricing**

   - The administration will focus on lowering prescription drug prices, including initiatives to allow the importation of cheaper drugs and promoting price transparency.

Regulatory Changes**

 The administration aims to speed up drug approvals and reduce regulatory burdens, which could enhance innovation and raise safety concerns.

Public Health Initiatives**

   - Efforts to address the opioid crisis will include funding for prevention and treatment programs.

Research Funding**

   - Changes in funding for agencies like the NIH could affect medical research, with potential shifts in focus areas depending on administration priorities.

Global Health**

   - The administration's approach to global health, including funding for organizations like the WHO, could influence international health initiatives.

The Trump administration's policies could have a lasting influence on the structure, accessibility, and affordability of healthcare in the U.S., shaping the landscape of medicine for years to come.

Other important Cabinet nominees are:

Trump's Cabinet picks?

Susie Wiles, 67, has been chosen for Chief of Staff. She was a senior advisor to Trump's 2024 presidential election and the first major decision that Trump announced after his win. Although not a Cabinet position, this is a key role in the White House.

Mike Waltz, 50, has been chosen for National Security Advisor. He is a Florida Congressman, a retired Army National Guard officer, and combat-decorated Green Beret. This position reports to the Secretary of Defense.

Tom Homan, 62, has been tapped as 'border czar' to oversee border control, again. He previously acted as Trump's head of Immigration and Customs Enforcement (ICE) and will join his new administration. Homan will report to the Secretary of Homeland Security.

Elise Stefanik, 40, has been chosen for United Nations ambassador. She is a New York congresswoman and has served as House Republican Conference chair since 2024 and would fill Trump's first U.N. ambassador role. Nikki Haley held this post in the last Trump administration. Though not a Cabinet position, ambassadors report to the Secretary of State.

Stephen Miller, 39, has been chosen to return as Deputy Chief of Staff for Policy. He served as a senior advisor in Trump's first administration and White House director of speechwriting. This is a key advisory role outside of the Cabinet.

Lee Zeldin, 44, has been chosen to lead the Environmental Protection Agency. He is a former New York congressman and officer in the United States Army Reserve. The EPA administrator is not in the Cabinet but is seen as a Cabinet-level role.

Kristi Noem, 52, has been picked to serve as secretary of the Department of Homeland Security. She is the Governor of South Dakota and is described as a "loyalist" who will be key to his domestic agenda.

Mike Huckabee, 55 a political commentator has been appointed as Ambassador to Israel

Organ Procurement and Transplantation Network (OPTN) Modernization Initiative | HRSA

Are you or a family member on a waiting list for a kidney, heart, or other organ transplant?  CMS and HRSA are working on finding and making available these organs for patients in need of an organ.




HRSA Makes Multi-Vendor Modernization Awards to Support the Nation’s Organ Transplant System

For the first time in 40 years, the Health Resources and Services Administration (HRSA) has awarded multiple contractors to apply their expertise and proven experience to improve the national organ transplant system. This transition from a single vendor to multiple vendors to support OPTN operations is a critical step in advancing innovation in the transplant system to better serve patients and their families. It also implements the bipartisan Securing the U.S. Organ Procurement and Transplantation Network Act signed by the President in September 2023.

As part of the first release of awards under the new Operations Transition contract, HRSA awarded multiple OPTN modernization awards to support critical actions, including:

  1. Improving Patient SafetyArbor Research Collaborative for Health will address patient safety and the policy compliance systems and processes overseen by the OPTN Board of Directors and the Membership and Professional Standards Committee to improve oversight of the multiple entities in the OPTN.  
  2. Supporting OPTN IT ModernizationGeneral Dynamics Information Technology, Inc. will focus on opportunities to improve the OPTN organ matching IT system and inform HRSA’s Next-Generation IT procurement and development work. 
  3. Increasing Transparency and Public Engagement in OPTN Policy DevelopmentMaximus Federal Services will advance opportunities to improve public visibility and engagement in the OPTN policy-making process including improving transparency around OPTN policy-making committees’ deliberations and actions.
  4. Strengthening Patient-Centered CommunicationsDeloitte Consulting will focus on improving communications from the OPTN, within the OPTN, and, importantly, with patients and families. 
  5. Improving OPTN Financial ManagementGuidehouse Digital will address improvements for OPTN’s budget development and management systems and processes. 

Together with HRSA’s actions earlier this summer to create a separate OPTN Board of Directors and award a new OPTN Board Support vendor, HRSA is taking critical and historic steps to modernize and improve the National organ transplant system– while ensuring access to lifesaving transplants continues without disruption.   

Artificial Intelligence can enhance the process as well

I can significantly enhance the process of finding organs for transplantation in several ways:


1. Matching Donors and Recipients

Data Analysis: AI algorithms can analyze vast amounts of data from donor and recipient medical records to identify the best matches based on compatibility factors, such as blood type, tissue type, and other health criteria.

Predictive Modeling: Machine learning models can predict which donors are likely to have organs that will be accepted by specific recipients, improving the chances of successful transplants.

2. Optimizing Organ Allocation

Logistics Management: AI can optimize the logistics of organ transportation by predicting the best routes and timing for organ delivery, ensuring that organs are transported efficiently and arrive in the best condition.

Resource Allocation: AI systems can help allocate organs not just based on medical needs but also by considering factors like geographical location and waiting times, ensuring a fair distribution.

3. Identifying Potential Donors

Health Records Analysis: AI can analyze electronic health records to identify potential organ donors more quickly, including those who may not have been considered otherwise.

Risk Assessment: Machine learning can help assess the risk factors associated with potential donors, aiding in the decision-making process for organ donation.

4. Monitoring and Predicting Outcomes

Post-Transplant Monitoring: AI can monitor recipients post-transplant, analyzing data from wearable devices and health records to predict complications and optimize recovery.

Long-Term Outcome Predictions: AI models can provide insights into the long-term success of transplants, helping to refine future matching processes.

5. Public Awareness and Education

Engagement Tools: AI can be used in chatbots and apps to educate the public about organ donation, improving awareness and potentially increasing the number of registered donors.

Conclusion

By leveraging AI technologies, the organ transplantation process can become more efficient, leading to better matches, improved outcomes, and ultimately, saving more lives.






August 2024  Updates






Organ Procurement and Transplantation Network (OPTN) Modernization Initiative | HRSA

Tuesday, November 12, 2024

What's Happening In Your Stomach? - Gastric Alimetry Review


There is a huge demand for a better understanding of the workings of our gastric systems, and so far, nobody has been able to meaningfully collect digital health data about them. Although the stomach is controlled by an electrical conduction system that regulates its contractions, the signals are a hundred times weaker than the heart's.

Imagine a device you wear that will measure the electrical activity of your gut. The technical challenge so far was to find a way to capture these mild signals in a clinically reliable way. A reliable solution that could either be used by patients at home or at the point of care would be a hit.

The Alimetry device has received FDA clearance. However, for the most current and accurate status regarding FDA approvals, it's best to check the official FDA website or consult recent news sources. Regulatory statuses can change, and new approvals or indications may have been granted.


What is in the ‘Body Surface Gastric Mapping System’ package?

A charger dock – with 4 different adapters for all kinds of global outlets, making the device universally usable. The dock needs to be plugged in to charge the reader
A reader with Bluetooth connectivity and wireless charging capability, you only need to place it on the dock, no wires are needed here. One confusing thing: once you pair your reader with the tablet, it stops showing battery charging levels, even if you disconnect them. The tricky part is that the app also keeps showing the battery charge level it had when it was paired, so you need to unpair and pair them again if you want to see the actual figure while charging  
Two packages of disposable arrays and array templates, each pair separately sealed
An iPad mini preinstalled with the Alimetry app – and locked to its exclusive use
A user manual booklet with very detailed information on the device, its parts, the setup, and the whole process.

What will the test deliver?

The test aims to detect the causes of overlapping gastric symptoms with distinct underlying phenotypes. In this study, researchers tested 43 patients with indistinguishable symptoms and were able to identify two distinct subgroups. 

The Gastric Alimetry platform is currently being used in clinical practice to differentiate between chronic nausea and vomiting syndromes (NVSs) that originate in the gut and those that arise through a centrally mediated pathway—a phenotype often tied to anxiety and depression.

The 64-channel reading of the Alimetry devices focuses on the fact that gastric dysfunctions are associated with abnormalities in the gastric bioelectrical slow waves. As shown in this study, the device was efficient in differentiating between patients having gastric neuromuscular disease or dysregulation of the brain-gut interaction. 

The tracing looks much like an electroencephalogram with multiple channels covering the abdomen. 

Conclusion

References:

American Journal of Gastroenterology. (a peer-reviewed article listed in PubMed, from the National Library of Medicine (NIH)  The American Journal of Gastroenterology 118(6):p 1047-1057, June 2023  DOI: 10.14309/ajg.0000000000002077

The Gastric Alimetry device is a first-of-a-kind solution, fully fitting all principles of digital health. It is making patients the point of care and it targets a niche area with massive demand. I am eager to see where Body Surface Gastric Mapping develops in the coming years.

The total time requirement of such a test is significant, patients need to dedicate a total of 10.5 hours to it. The discomfort of the prolonged process is tolerable, many gastric diagnostic methods are much more demanding. If you have chronic NVS and would like to find a way to detect its causes, it is well worth the effort. 

At the moment it seems Alimetry is a good tool to detect the underlying causes of chronic NVS, and the company is working on how to apply it to other gastrointestinal conditions, including functional dyspepsia and gastroparesis.

Saturday, November 9, 2024

Concierge Medicine---Consider it


Direct Primary Care, with a monthly prepaid contract.

If you are young and fairly healthy with minor issues this plan costs less than your health insurance plan. You can supplement it with a major medical plan.







Unger’s blog | SignatureMD

Friday, November 8, 2024

The Nobel Prize in Physics 1901 - An illuminating accident - NobelPrize.org


Wilhelm Conrad Röntgen
The Nobel Prize in Physics 1901

Born: 27 March 1845, Lennep, Prussia (now Remscheid, Germany)

Died: 10 February 1923, Munich, Germany

Affiliation at the time of the award: Munich University, Munich, Germany


 Röntgen studied cathode radiation, which occurs when an electrical charge is applied to two metal plates inside a glass tube filled with rarefied gas. Although the apparatus was screened off, he noticed a faint light on light-sensitive screens that happened to be close by. Further investigations revealed that this was caused by a penetrating, previously unknown type of radiation. X-ray radiation became a powerful tool for physical experiments and examining the body's interior.



The Nobel Prize in Physics 1901 - Speed read: An illuminating accident - NobelPrize.org

Salivary Enzyme Behind Our Carb Cravings May Have Unexpectedly Ancient History – NIH Director's Blog

                   

In today's world our diet is far different from that of prehistoric man and even that of several centuries ago. Modern diets now contain many processed and genetically modified wheats, grains and domesticated animals such as cows, poultry, and pigs.
These foods are altered by freezing, and preservation.  In addition to those alterations they are not fresh, nor eaten immediately after harvesting or processing.
The packaging is often plastic leading to contamination with micro plastic particles.
Studies reveal microplastic particles in water, and in our blood stream. Microplastics are not biologically active and remain for indefinite periods.  It is not yet known what effects this will have on living systems.

Microplastic particles in blood



Microscopy of Intestine. A,B controls. C,D post ingestion of MP

Digestion involves much more than just your stomach. The digestive process that fuels your body begins in your mouth each time you take a bite of food and chew. An enzyme in your saliva, called amylase, then starts to break down complex carbohydrates—or starches found in many fruits, vegetables, and grains—into simpler sugars to give you their sweet flavor followed by a burst of energy.

Amylase is the reason we’re so good at turning starch into calories, but it isn’t the same for everyone. There’s plenty of genetic variation in the number of salivary amylase genes (AMY1) our cells carry and, therefore, in how much of this essential starch-busting enzyme people have. Studies have suggested a link between changes in amylase gene copy numbers over time and both the rise of agriculture and starch-heavy diets. Now a study in Science , supported in part by NIH, suggests that extra copies of AMY1 are not only connected to our ability to effectively digest carbs, but also may be more ancient than previously known, arising even before modern humans split from Neanderthals and long before the advent of farming.

Genomic studies reveal the amylase protein has evolved since paleolithic times.

The new findings come from a research team led by Omer Gokcumen  at The University of Buffalo, NY, and Charles Lee  of The Jackson Laboratory for Genomic Medicine, Farmington, CT.

JAX Farmington, CT

JAX Bar Harbor, ME

This variation in amylase genes would have afforded our ancestors dietary flexibility, allowing them to adapt as diets changed over time. But these discoveries aren’t only fascinating from an evolutionary or historical point of view. They may also lead to new understandings of genetic differences among people today, with potentially important implications for our metabolisms, nutrition, and health.
















Salivary Enzyme Behind Our Carb Cravings May Have Unexpectedly Ancient History – NIH Director's Blog